Omeprazole vs Ranitidine in Reflux Oesophagitis in Sweden

PharmacoEconomics: PharmacoEconomics

Volumn 5, Issue 3, 1994, Pages 27-34

  Lindberg, Greger ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001834308     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-199400053-00006     Document Type: Article

References (16)

1. Reflux esophagitis resolves more rapidly with omeprazole 20mg once daily than with ranitidine 150mg twice daily: omeprazole 40mg once daily provides further benefit in unresponsive patients
2. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations
3. Omeprazole is superior to ranitidine in the treatment of reflux esophagitis
4. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine
5. Healing and relapse of severe peptic esophagitis after treatment with omeprazole
6. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis
7. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials
8. Prospective evaluation of ‘GLADYS’ — a system for computer assisted diagnosis of dyspepsia
9. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ‘standard doses’ of H2-receptor antagonists
10. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study
11. Investigation of ranitidine 150mg bd or 300 mg bd in the treatment of reflux disease
12. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers
13. Omeprazole (40mg) is superior to ranitidine in short-term treatment of ulcerative reflux oesophagitis
14. Treatment of reflux oesophagitis with ranitidine
15. Omeprazole (20 mg/day) compared with ranitidine (150mg twice daily) in the treatment of reflux oesophagitis. Results of a randomised double-blind multicentre Franco-Belgian trial